Print

Global CRO ClinTec GmbH and Elephant Capital Complete Strategic £8 Million Investment Deal  
8/19/2010 8:45:19 AM

Glasgow, Scotland, UK August 19, 2010 -- ClinTec International, a global Clinical Research Organisation (“CRO”) announces a financial and strategic partnership with Elephant Capital Plc., an AIM market listed private equity firm. With an investment of £8 Million GBP, Elephant has acquired a significant minority stake in ClinTec. Through this investment, Elephant has entered the attractive clinical research base, where ClinTec operates as a global provider of outsourcing solutions addressing the drug development lifecycle. Managing Partner of Elephant Capital LLP, Gaurav Burman, and Non-Executive Director of Elephant Capital Plc, Jim Hauslein, have also made personal co-investments in this transaction.

ClinTec has elected to strengthen the Board of the company as part of the transaction, and as such Gaurav Burman, Dr Anand Burman and Jim Hauslein will take up seats on the Board. Gaurav Burman founded Elephant Capital in 2007; the company counts some of the leading financial institutional investors in the UK and Europe amongst its shareholders and is actively supported by the Burman family itself. Dr Anand Burman is the Chairman of FMCG company Dabur, and brings a wealth of experience in the healthcare sector and oncology. Jim Hauslein, who has previously served as Chairman and CEO of Sunglass Hut International, which was turned into a global enterprise during his tenure, provides invaluable business experience of growing corporates internationally.

Elephant focuses on differentiated businesses which are able to leverage the potential India holds as an emerging powerhouse within the global economy. ClinTec was identified as just such a company, as it has established a solid presence in India and is one of the first-movers in the Clinical Research Services arena to enter India in 2002. Elephant Capital will leverage their substantial network in India and internationally, to aid the further expansion of ClinTec operations in India. The partnership will also facilitate expansion into the Asia Pacific region with ClinTec’s long established Bangalore office serving as the regional hub for clinical research activity.

President and CEO, Dr Rabinder Buttar founded ClinTec in 1997 and has since then organically grown the company into a global multi-national. Dr Buttar commented, “ For more than a decade ClinTec’s highly experienced teams across the globe supported by expert country managers have been driving the growth of our organisation, ClinTec provides high quality clinical research services and resourcing solutions to clients who include 11 of the top 25 global pharmaceutical companies, plus innovative biotech and medical device companies. As the pharmaceutical and biotech industry shifts its drug development efforts to the emerging markets, ClinTec will partner with its clients in a flexible way, exactly aligning its services and operations to fit with the needs of its clients. We value the strategic input of Elephant, the Burman family and their wealth of experience in Dabur, as well as the extensive experience of our US Board Director, James Hauslein. With a new global Board in place and hugely committed employees in every continent, we are very optimistic about the continued strong growth of ClinTec ahead.”

Commenting on the transaction, Gaurav Burman said. “We are looking forward to a long-term partnership with ClinTec International and building on all that has been achieved to date. As well as bringing to ClinTec, our expertise in finance and creating corporate global organisations, we look to preserve the fine values and unique culture of ClinTec which has made it such a well respected and successful global organisation”.

ClinTec’s Senior Director of Corporate Development, Mr Bobby Bal commented, ”The investment is further confirmation of the quality within the ClinTec business, which is very much driven by our employees delivering outstanding client service all over the world. We are pleased to bring Elephant on board to further enhance our development within Asia, which will be of huge benefit for our client base. We look forward to strategically working with Elephant on a global basis over the coming years”.

If you would like further information on ClinTec International, please contact:

Bobby Bal, Senior Director, Corporate Development, Glasgow, Scotland, UK Phone: +44 (0)141 226 1120 Fax: +44 (0)141 248 8993 Email : cdean@clintec.com www.clintec.com

Media Enquiries:

Tristan Jervis or Alex Heeley Phone: 00 44 207 861 3838 E-mail: t.jervis@defacto.com / a.heeley@defacto.com

About ClinTec International

ClinTec is a global contract clinical research organisation, established in 1997 by Dr Rabinder Buttar, the company’s President and CEO. ClinTec has a presence in over 40 developed and emerging countries, covering Western Europe, Central & Eastern Europe, the Middle East and North Africa, Central and South Africa, Latin America, Asia Pacific and the US. In addition to ClinTec’s vast expertise in oncology, the organisation has also conducted over 250 clinical trials in other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world-class project managers and clinical research associates. ClinTec’s fast, flexible and focused approach to clinical research ensures an added advantage to the drug development process. The organisations range of services includes Clinical Monitoring and Project Management, Regulatory Affairs, Medical Writing, Data Management and Biostatistics, Global Clinical Resourcing, Quality Assurance, Drug Development Consultancy and Clinical Training courses.

For more information about ClinTec, please visit www.clintec.com


//-->